Cargando…

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues

Background: The WHO classification of non-pituitary neuroendocrine tumors (NETs) includes grading (Ki67 proliferation index and mitosis index) and staging, and has been shown to be associated with outcome in this patient population. Neuroendocrine tumors show different somatostatin receptor (SSTR) s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqui, Abdullah, Hosseini, Alireza, Marandi, Roghayeh, Salehian, Behrouz, Chang, Sue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Tumor Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209549/ http://dx.doi.org/10.1210/jendso/bvaa046.2006

Ejemplares similares

SAT-LB059 NET or NOT: Physiological Uptake in Pancreatic Head on Somatostatin Receptor Based Imaging
por: Jhawar, Sakshi, et al.
Publicado: (2019)

SAT-127 Localization and Treatment of the Ectopic ACTH Syndrome Using Somatostatin Analogues
por: Mago, Sheena, et al.
Publicado: (2020)

SAT-117 Refractory Paraneoplastic Non Islet Cell Tumor Hypoglycemia (NICTH) from Hepatocellular Carcinoma Managed with Somatostatin Analogue and Glucocorticoids
por: Siddiqui, Mahwash Fatima, et al.
Publicado: (2020)

SUN-323 Somatostatin Analogue: An Effective Treatment for Pseudoglucagonoma Syndrome
por: Vallejo Garcia, Franco, et al.
Publicado: (2019)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

The role of somatostatin analogues in treatment of TSH secreting pituitary adenomas
por: Zgliczyński, Wojciech, et al.
Publicado: (2013)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

SAT-315 SDHC Germline Mutation Carrier with Primary Paraganglioma of the Thyroid Gland
por: Lee, Hyunju, et al.
Publicado: (2019)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

SUN-118 Somatostatin Agonist Conjugated to the Evans Blue Moiety Is a Superior Analog in the Diagnosis and Treatment of Tumors Characterized by High Somatostatin Receptor Expression
por: Thakur, Shilpa, et al.
Publicado: (2020)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4
por: Börzsei, Rita, et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

SAT-LB307 Case of the Broken Hearted
por: Namboodiri, Divya, et al.
Publicado: (2020)

Case Series of Metastatic VIPoma With Partial Response to Somatostatin Receptor Ligand and Review of Therapeutic Options
por: Wen, Lim Sue, et al.
Publicado: (2021)

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways
por: Cakir, Mehtap, et al.
Publicado: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications
por: Cakir, Mehtap, et al.
Publicado: (2010)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
por: Liu, Wenjuan, et al.
Publicado: (2017)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

SAT-LB314 Not That Sweet Honeymoon: A Case of Proinsulinoma
por: Maldonado, Francisco Javier Lopez, et al.
Publicado: (2020)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ngg475703772qhi4ffd6bprs3g